Can-Fite BioPharma (CANF) EBITDA Margin (2015 - 2023)
Can-Fite BioPharma's (CANF) quarterly EBITDA Margin came in at 1183.23% in Q4 2023, down 27400.0% YoY from N/an in Q4 2022, and down 24.35% on a QoQ basis from 951.53% in Q3 2023.
Can-Fite BioPharma (CANF) EBITDA Margin (2015 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 9 years of EBITDA Margin data on file, last reported at 1183.23% in Q4 2023.
- Quarterly EBITDA Margin fell 27400.0% year-over-year to 1183.23% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 1102.96% (changed 0.0% YoY) and the FY2025 annual result came in at 2456.79%, down 125056.0% from the prior year.
- EBITDA Margin retreated to 1183.23% in Q4 2023, from 951.53% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 572.24% in Q1 2019 to a low of 2401.56% in Q4 2019.
- A 5-year average of 1306.96% and a median of 1257.24% in 2021 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2020 — EBITDA Margin plunged 273184 bps — and 2022, when it surged 106528 bps.
- Tracing CANF's EBITDA Margin over 5 years: stood at 2401.56% in 2019, then climbed by 1 bps to 2368.67% in 2020, then increased by 17 bps to 1974.51% in 2021, then surged by 54 bps to 909.23% in 2022, then slumped by 30 bps to 1183.23% in 2023.
- The last three EBITDA Margin figures came in at 1183.23% (Q4 2023), 951.53% (Q3 2023), and 910.2% (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1,183.23% |
| Sep 30, 2023 | -951.53% |
| Jun 30, 2023 | -910.20% |
| Mar 31, 2023 | -1,383.67% |
| Dec 31, 2022 | -909.23% |
| Sep 30, 2022 | -1,261.27% |
| Jun 30, 2022 | -1,014.71% |
| Mar 31, 2022 | -1,156.10% |
| Dec 31, 2021 | -1,974.51% |
| Sep 30, 2021 | -1,398.41% |
| Jun 30, 2021 | -1,253.20% |
| Mar 31, 2021 | -1,466.89% |
| Dec 31, 2020 | -2,368.67% |
| Sep 30, 2020 | -1,174.88% |
| Jun 30, 2020 | -1,877.94% |
| Mar 31, 2020 | -2,159.60% |
| Dec 31, 2019 | -2,401.56% |
| Sep 30, 2019 | -242.27% |
| Jun 30, 2019 | -1,623.65% |
| Mar 31, 2019 | 572.24% |